COMMUNIQUÉS West-GlobeNewswire

CareDx to Announce Third Quarter 2018 Financial Results on November 8, 2018

17/10/2018 - 14:00

BRISBANE, Calif., Oct. 17, 2018 (GLOBE NEWSWIRE) -- CareDx, Inc. (Nasdaq: CDNA), a molecular diagnostics company focused on the discovery, development and commercialization of clinically differentiated, high-value [...]

Intra-Cellular Therapies Presents Results from ITI-214 Phase 1/2 Clinical Trial in Patients with Parkinson’s Disease at 2018 American Neurological Association Annual Meeting

17/10/2018 - 14:00

NEW YORK, Oct. 17, 2018 (GLOBE NEWSWIRE) -- Intra-Cellular Therapies, Inc. (Nasdaq:ITCI), a biopharmaceutical company focused on the development of therapeutics for central nervous system (CNS) disorders, today [...]

IntelGenx Receives Over $1.6 Million from Exercise of Warrants

17/10/2018 - 14:00

SAINT LAURENT, Quebec, Oct. 17, 2018 (GLOBE NEWSWIRE) -- IntelGenx Technologies Corp. (TSX-V: IGX) (OTCQX: IGXT) (the “Company” or “IntelGenx”) is pleased to announce that, since September 15, 2018, it has received [...]

Clinical Laserthermia Systems (CLS) Signs Exclusive Distribution Agreement with MRI Interventions for USA and Canada

17/10/2018 - 14:00

2-Year Agreement Enables MRI Interventions to Distribute CLS’s Precision Ablation Product Portfolio for Use in Interventional MR-Guided Procedures Beyond their Previously Announced Spine and Neuro License Agreement [...]

Former UnitedHealth Group Cancer Director Dr. Lee Newcomer Joins Cellworks Board of Directors

17/10/2018 - 14:00

Leading Precision Medicine Company Adds to Prestigious Board of Directors, which includes Dr. David Lawrence, Dr. Allen Lichter and Dr. Bill Rutter SAN JOSE, Calif., Oct. 17, 2018 (GLOBE NEWSWIRE) -- Cellworks Group, [...]

aTyr Pharma Presents at American Society of Human Genetics 2018 Meeting

17/10/2018 - 14:00

SAN DIEGO, Oct. 17, 2018 (GLOBE NEWSWIRE) -- aTyr Pharma, Inc. (Nasdaq: LIFE), a biotherapeutics company engaged in the discovery and development of innovative medicines based on novel immunological pathways, today [...]

Intensity Therapeutics to Present Preliminary Data from Clinical Study of INT230-6 at Upcoming Medical Conferences

17/10/2018 - 13:35

Posters at European Society for Medical Oncology (ESMO) 2018 Congress and Society for Immunotherapy of Cancer (SITC) 33 rd Annual Meeting to highlight safety of intratumoral INT230-6 in patients with advanced solid [...]

MRI Interventions and Clinical Laserthermia Systems (CLS) Announce Collaboration to Develop Next-Generation Navigation and Laser Ablation Platforms for Neurosurgery

17/10/2018 - 13:30

Under the terms of the agreement, MRIC acquires worldwide exclusive rights to the platform for use in Neurosurgery and Spine with CLS as manufacturer IRVINE, Calif. and LUND, Sweden, Oct. 17, 2018 (GLOBE NEWSWIRE) -- [...]

MRI Interventions and Clinical Laserthermia Systems (CLS) Announce Collaboration to Develop Next-Generation Navigation and Laser Ablation Platforms for Neurosurgery

17/10/2018 - 13:30

Under the Terms of the Agreement, MRIC Acquires Worldwide Exclusive Rights to the Platform for Use in Neurosurgery and Spine with CLS as Manufacturer IRVINE, Calif. and LUND, Sweden, Oct. 17, 2018 (GLOBE NEWSWIRE) -- [...]

ADMA Biologics Receives PDUFA Date for RI-002

17/10/2018 - 13:08

Resubmission of Biologics License Application (“BLA”) Reinforces the Company’s Commitment to Commercialize Novel Therapies for Immune Compromised Patients to Address Unmet Medical Needs RAMSEY, N.J. and BOCA RATON, Fla [...]

Sonoma Pharmaceuticals Launches New Ceramax™ Skin Barrier Lotion with Skin-Enriching Lipogrid Technology™

17/10/2018 - 13:05

PETALUMA, Calif., Oct. 17, 2018 (GLOBE NEWSWIRE) -- Sonoma Pharmaceuticals, Inc. (Nasdaq: SNOA), a specialty pharmaceutical company that develops and markets unique and effective solutions for the treatment of [...]

Amryt Pharma plc: Lojuxta to be reimbursed in France

17/10/2018 - 13:00

17 October 2018 AIM: AMYT ESM: AYP Amryt Pharma plc (“Amryt” or the “Company”) Lojuxta to be reimbursed in France Amryt’s lead commercial product now available in all five of the EU’s largest markets Amryt, a revenue [...]

Aeglea BioTherapeutics Announces New Positive Interim Clinical Data and Improvements in Disease Manifestations for Ongoing Phase 1/2 Trial of Pegzilarginase in Patients with Arginase 1 Deficiency

17/10/2018 - 13:00

Pegzilarginase is Effective in Sustainably Lowering Plasma Arginine Levels Clinically Significant Improvements After Eight Doses Included Effects on Mobility and Adaptive Behavior Company to Host Clinical Update [...]

CLS Signs Agreement with Image Guided Therapy to Develop and Commercialize Product for MR-Generated Temperature Monitoring

17/10/2018 - 13:00

FRAMINGHAM, Mass., Oct. 17, 2018 (GLOBE NEWSWIRE) -- CLS AB in Lund, Sweden, with the subsidiary Clinical Laserthermia Systems Americas, Inc . (CLS Americas), today announced it has signed an agreement with Image Guided [...]

NeuroMetrix Reports Q3 2018 Financial Results

17/10/2018 - 13:00

$3.8M GSK Milestone; Improved Operating Performance WALTHAM, Mass., Oct. 17, 2018 (GLOBE NEWSWIRE) -- NeuroMetrix, Inc. (Nasdaq: NURO), today reported financial and business highlights for the quarter ended September 30 [...]

Iovance Biotherapeutics, Inc. Announces Closing of $252 Million Common Stock Public Offering

17/10/2018 - 13:00

Offering Includes Exercise in Full of the Underwriter’s Option to Purchase an Additional 3.3 Million Shares of Common Stock SAN CARLOS, Calif., Oct. 17, 2018 (GLOBE NEWSWIRE) -- Iovance Biotherapeutics, Inc. (Nasdaq: [...]

Aleafia Launches Three New Clinics, Telemedicine Treatment in Significant Expansion

17/10/2018 - 13:00

Six Physicians, Nurse Practitioners Also Joining Canabo Medical Clinics TORONTO, Oct. 17, 2018 (GLOBE NEWSWIRE) -- Aleafia Health Inc. ( TSXV: ALEF; OTCQX: ALEAF, FRA: ARAH ) (“ Aleafia “) or (the “Company“), one of [...]

Axsome Therapeutics Receives FDA Orphan Drug Designation for AXS-12 for the Treatment of Narcolepsy

17/10/2018 - 13:00

NEW YORK, Oct. 17, 2018 (GLOBE NEWSWIRE) -- Axsome Therapeutics, Inc. (NASDAQ: AXSM), a clinical-stage biopharmaceutical company developing novel therapies for the management of central nervous system (CNS) disorders, [...]

Auris Medical Announces Positive Results From Second Phase 1 Clinical Trial With Intranasal Betahistine

17/10/2018 - 12:45

Bioavailability significantly higher than with oral administration Treatment safe and multiple dosing well tolerated Company to move forward with planned proof-of-concept studies in acute vertigo and olanzapine-induced [...]